MedTrace Logo

This is a Phase 1 Study of MH048 in Patients With Selected Relapsed/Refractory B-cell Malignancies

NCT04689308 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2021-09-08

No results posted yet for this study

Summary

This is a Phase 1 study of MH048 in patients with selected Relapsed/Refractory B-cell Malignancies.

Conditions

  • Relapsed/Refractory B-cell Malignancies

Interventions

DRUG

MH048

Soft gel capsules 5 mg and 25 mg，oral MH048 should be administered after an overnight fast.

Sponsors & Collaborators

  • Minghui Pharmaceutical (Shanghai) LTD

    lead INDUSTRY

Principal Investigators

  • Jie Jin, MD · 79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang, China

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-07
Primary Completion
2023-06-30
Completion
2023-10-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04689308 on ClinicalTrials.gov